Abstract
The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping. Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses. Such particles possess the tropism of the virus from which the GP was derived. For example, to exploit the natural neural tropism of rabies virus, vectors designed to target the central nervous system have been pseudotyped using rabies virus-derived GPs. Among the first and still most widely used GPs for pseudotyping lentiviral vectors is the vesicular stomatitis virus GP (VSV-G), due to the very broad tropism and stability of the resulting pseudotypes. Pseudotypes involving VSV-G have become effectively the standard for evaluating the efficiency of other pseudotypes. This review samples a few of the more prominent examples from the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and hostcell specificity. Particular attention is paid to publications of successfully targeting a specific organ or cell types.
Keywords: lentiviral vector, gene therapy, glycoproteins, vector tropism
Current Gene Therapy
Title: Altering the Tropism of Lentiviral Vectors through Pseudotyping
Volume: 5 Issue: 4
Author(s): James Cronin, Xian-Yang Zhang and Jakob Reiser
Affiliation:
Keywords: lentiviral vector, gene therapy, glycoproteins, vector tropism
Abstract: The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping. Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses. Such particles possess the tropism of the virus from which the GP was derived. For example, to exploit the natural neural tropism of rabies virus, vectors designed to target the central nervous system have been pseudotyped using rabies virus-derived GPs. Among the first and still most widely used GPs for pseudotyping lentiviral vectors is the vesicular stomatitis virus GP (VSV-G), due to the very broad tropism and stability of the resulting pseudotypes. Pseudotypes involving VSV-G have become effectively the standard for evaluating the efficiency of other pseudotypes. This review samples a few of the more prominent examples from the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and hostcell specificity. Particular attention is paid to publications of successfully targeting a specific organ or cell types.
Export Options
About this article
Cite this article as:
Cronin James, Zhang Xian-Yang and Reiser Jakob, Altering the Tropism of Lentiviral Vectors through Pseudotyping, Current Gene Therapy 2005; 5 (4) . https://dx.doi.org/10.2174/1566523054546224
DOI https://dx.doi.org/10.2174/1566523054546224 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Synthesis of [DTPA-bis(D-ser)] Chelate (DBDSC): An Approach for the Design of SPECT Radiopharmaceuticals Based on Technetium
Current Radiopharmaceuticals Microdialysis: A Technique for Pharmacokinetic-Pharmacodynamic Studies of Oncological Drugs
Current Pharmaceutical Biotechnology Melatonin Receptor as a Drug Target for Neuroprotection
Current Molecular Pharmacology New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics Preclinical Molecular Imaging of the Translocator Protein (TSPO) in a Metastases Model Based on Breast Cancer Xenografts Propagated in the Murine Brain
Current Molecular Medicine Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets Proteomic Analysis of Glioma Chemoresistance
Current Neuropharmacology Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal